Preventing pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis: cost effectiveness of IgG4.
Hughes
Duncan B
DB
Grobmyer
Stephen R
SR
Brennan
Murray F
MF
D001327:Autoimmune Diseases / Q000097:blood / Q000175:diagnosis* / Q000191:economics / Q000276:immunology / Q000601:surgery; D015415:Biomarkers; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003937:Diagnosis, Differential; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000276:immunology; D016577:Pancreaticoduodenectomy / Q000191:economics; D010195:Pancreatitis / Q000097:blood / Q000175:diagnosis* / Q000191:economics / Q000276:immunology / Q000601:surgery; D011300:Preoperative Care; D019564:Unnecessary Procedures
D015415:Biomarkers; D007074:Immunoglobulin G